Three-month Treatment Response and Exacerbation in Chronic Obstructive Pulmonary Disease.
10.3346/jkms.2015.30.1.54
- Author:
Jung Su LEE
1
;
Chin Kook RHEE
;
Kwang Ha YOO
;
Ji Hyun LEE
;
Ho Il YOON
;
Tae Hyung KIM
;
Woo Jin KIM
;
JinHwa LEE
;
Seong Yong LIM
;
Tai Sun PARK
;
Jae Seung LEE
;
Sei Won LEE
;
Sang Do LEE
;
Yeon Mok OH
Author Information
1. Department of Pulmonary and Critical Care Medicine, and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ymoh55@amc.seoul.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Pulmonary Disease, Chronic Obstructive;
Forced Expiratory Volume;
Disease Progression
- MeSH:
Adrenal Cortex Hormones/*therapeutic use;
Adrenergic beta-2 Receptor Agonists/*therapeutic use;
Bronchodilator Agents/*therapeutic use;
Budesonide/therapeutic use;
Drug Therapy, Combination;
Female;
Fluticasone/therapeutic use;
Forced Expiratory Volume/drug effects/*physiology;
Formoterol Fumarate/therapeutic use;
Humans;
Male;
Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology;
Recurrence;
Republic of Korea;
Salmeterol Xinafoate/therapeutic use;
Smoking;
Spirometry;
Treatment Outcome
- From:Journal of Korean Medical Science
2015;30(1):54-59
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this study was to investigate relationships between acute exacerbation and Forced Expiratory Volume 1 second (FEV1) improvement after treatment with combined long-acting beta-agonist (LABA) and inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD). A total of 137 COPD patients were classified as responders or nonresponders according to FEV1 improvement after 3 months of LABA/ICS treatment in fourteen referral hospitals in Korea. Exacerbation occurrence in these two subgroups was compared over a period of 1 yr. Eighty of the 137 COPD patients (58.4%) were classified as responders and 57 (41.6%) as nonresponders. Acute exacerbations occurred in 25 patients (31.3%) in the responder group and in 26 patients (45.6%) in the nonresponder group (P=0.086). FEV1 improvement after LABA/ICS treatment was a significant prognostic factor for fewer acute exacerbations in a multivariate Cox proportional hazard model adjusted for age, sex, FEV1, smoking history, 6 min walk distance, body mass index, exacerbation history in the previous year, and dyspnea scale.Three-month treatment response to LABA/ICS might be a prognostic factor for the occurrence of acute exacerbation in COPD patients.
